The Barcelona Supercomputing Centre – National Supercomputing Centre, which is a worldwide center in Barcelona, Spain, has entered into a new agreement with Almirall, a biopharmaceutical company working on various medical aspects. This agreement will help speed up dermatology research using supercomputers. Furthermore, the partnership reflects Almirall’s strong commitment to scientific innovation. The company continues to address unmet patient needs in dermatology. It builds on previously successful R&D projects. Moreover, it strengthens an already established research collaboration framework.
As part of this initiative, Almirall joins the ‘BSC Connects’ program. This program promotes public-private collaboration.It also promotes R&D excellence within industries. The company has the opportunity to acquire technological advancements and professional training through such cooperation. Moreover, customized support is provided for the development of new initiatives up until 2026.
Through the collaboration, Almirall will be able to incorporate disruptive technologies into the research process. It contributes to drug development and discovery and benefits patients who suffer from skin conditions. It will allow researchers from both institutions to tackle challenging cases related to the field of dermatology. With the help of their scientific knowledge, they can identify groundbreaking innovations. These efforts include research in genomics, digital twins, and drug design.
“Our passion for medical dermatology drives us to constantly seek innovative solutions that can make a real difference in patients’ lives” stated Dr. Karl Ziegelbauer, Chief Scientific Officer at Almirall. “Strengthening our collaboration with a world-class institution like BSC is a crucial step in our journey. By combining their expertise in supercomputing and AI with our deep understanding of dermatology, we are creating a powerful synergy to accelerate the development of the next generation of skin treatments. This initiative aligns perfectly with our vision of being at the forefront of science and technology to transform patients’ lives and represents a key pillar in accelerating our ability to discover and develop innovative therapies.”
Meanwhile, BSC continues to lead as a global research center. It plays a vital role in Europe’s supercomputing ecosystem. The ‘BSC Connects’ initiative creates a strong collaboration platform. It connects industry leaders with academic research communities.
As Mateo Valero, Director of BSC, stated “This agreement with Almirall, within the framework of the BSC Connects program, is an example of how supercomputing and artificial intelligence can be placed at the service of industry to generate a real impact on people’s health. BSC and Almirall share a vision of collaboration rooted in a broader research partnership and the use of technology as a driver of innovation. Together we can contribute to advancing the field of medical dermatology by providing tools and capabilities that make a real difference.”
BSC Connects Drives Industry and Science Collaboration
BSC Connects serves as a business immersion program designed to accelerate collaboration. It bridges the gap between scientific research and industry applications. The program enables organizations to access advanced computing resources and scientific expertise.
Additionally, it offers specialized training and project development opportunities. Participants can collaborate on European initiatives and industry use cases. The program also supports strategic networking across global innovation ecosystems.
Moreover, BSC Connects follows a structured approach to innovation. It identifies technological challenges and evaluates outcomes effectively. It also promotes collaboration through global events and forums. As a result, it strengthens the connection between science and business innovation.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
